Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Coordination of Locomotor Activity in Transgenic C57Bl/6 Mice with Hereditary Neuropathy

  • 6 Accesses

Locomotor activity of C57Bl/6 mice with hereditary motor and sensory neuropathy (HMSN; an animal model of Charcot–Marie–Tooth, CMT, disease) was investigated in males and females of two ages (15 and 20 weeks) using the balance beam test (inclined beam); such indices as time of traveling via the beam to the shelter and number of slippings of the hindlimbs from the beam were recorded. It was found that C57Bl/6 mice spent dramatically more time for traveling than control C57Bl mice with no neuropathy, and the number of erroneous movements (slippings of the hindlimbs) during traveling in mice with HMSN was many times greater than that in the controls. The deficiency of control of locomotion in C57Bl/6 animals was found to be sex- and age-dependent. Females of this strain moved significantly slower than males of the same age categories; both 20-week-old males and females with HMSN spent significantly more time for traveling the test distance than 15-week-old animals and demonstrated more motor failures. Thus, symptoms of HMSN are more pronounced in females (probably due to the specificity of the hormonal background in the latter), and the severity of pathology increases with age. The balance beam test appears acceptable for obtaining easily interpretable quantitative characteristics of the quality of locomotion control in experimental animal models of neuropathies.

This is a preview of subscription content, log in to check access.


  1. 1.

    D. Caruso, S. Scurati, I. Roglio, et al., “Neuroactive steroid levels in a transgenic rat model of CMT1A neuropathy,” J. Mol. Neurosci., 34, No. 3, 249–253, (2008).

  2. 2.

    L. L. Kirkpatrick, A. S. Witt, H. R. Payne, et al., “Changes in microtubule stability and density in myelindeficient shiverer mouse CNS axons,” J. Neuroscience, 21, No. 7, 2288–2297 (2001).

  3. 3.

    J. C. MacMillan, and P. S. Harper, “The Charcot-Marie-Tooth syndrome: clinical aspects from a population study in South Wales, UK,” Clin. Genet., 45, No. 3, 128–134 (1994).

  4. 4.

    L. Wrabetz, M. L. Feltri, A. Quttrini, et al., “P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves,” J. Cell. Biol., 148, No. 5, 1021–1034 (2000).

  5. 5.

    G. A. Nicholson, “Penetrance of the hereditary motor and sensory neuropathy 1a mutation: assessment by nerve conduction studies,” Neurology, 41, No. 4, 547–552 (1991).

  6. 6.

    P. J. Dyck, P. Chance, R. Lebo, and J. A. Carney, “Hereditary motor and sensory neuropathies,” In: Peripheral Neuropathy, P. J. Dyck, P. K. Thomas, J. W. Griffin, et al. (eds), 3rd ed., WB Saunders, Philadelphia, 1094–1136 (1993).

  7. 7.

    M. Sereda, I. Griffiths, A. Pühlhofer, et al., “A transgenic rat model of Charcot-Marie-Tooth disease,” Neuron, 16, No. 5, 1049–1060 (1996).

  8. 8.

    A. Wallace, A. Pietrusz, E. Dewar, et al., “Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity,” Neurology, 92, No. 15, e1773–e1785 (2019).

  9. 9.

    V. Prada, S. Schizzi, I. Poggi, et al., “Hand rehabilitation treatment for Charcot-Marie-Tooth disease: An open label pilot study,” J. Neurol. Neurophysiol., 9, No. 4, 465 (2018).

  10. 10.

    R. Chetlin, L. Gutmann, M. Tarnopolsky, et al., “Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription,” Arch. Phys. Med. Rehabil., 85, No. 8, 1217–1223 (2004).

  11. 11.

    J. Morena, A. Gupta, and J. C. Hoyle, “Charcot-Marie-Tooth: from molecules to therapy,” Int. J. Mol. Sci., 20, No. 14, E3419 (2019).

  12. 12.

    I. O. Govbakh, D. O. Zavodovskiy, N. V. Bulgakova, et al., “Nerve conduction and neuromuscular transmis-sion in C57Bl/6 mice with genetically determined peripheral neuropathy,” Neurophysiology, 51, No. 4, 248–252 (2019).

  13. 13.

    S. Ekins, N. K. Litterman, R. J. Arnold, et al., “A brief review of recent Charcot-Marie-Tooth research and priorities,” F1000Res., 4, 53 (2015).

  14. 14.

    M. E. Walsh, L. B. Sloane, K. E. Fischer, et al., “Use of nerve conduction velocity to assess peripheral nerve health in aging mice,” J. Gerontol. A. Biol. Sci. Med. Sci., 70, No. 11, 1312–1319 (2015).

  15. 15.

    L. Padua, I. Aprile, T. Cavallaro, et al., “Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicentre study,” Neurol. Sci., 27, No. 6, 417–423 (2006).

  16. 16.

    M. W. Sereda, G. Meyer zu Hörste, U. Suter, et al., “Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A),” Nat. Med., 9, No. 12, 1533–1537 (2003).

  17. 17.

    V. Magnaghi, S. Veiga, M. Ballabio, et al., “Sexdimorphic effects of progesterone and its reduced metabolites on gene expression of myelin proteins by rat Schwann cells,” J. Peripher. Nerv. Syst., 11, No. 2, 111–118 (2006).

Download references

Author information

Correspondence to D. O. Zavodovskiy.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Govbakh, I.O., Zavodovskiy, D.O., Bulgakova, N.V. et al. Coordination of Locomotor Activity in Transgenic C57Bl/6 Mice with Hereditary Neuropathy. Neurophysiology 51, 353–357 (2019).

Download citation


  • locomotor activity
  • balance beam test
  • peripheral neuropathy
  • transgenic C57Bl/6 mice
  • Charcot–Marie–Tooth disease